Clinical outcomes of nivolumab plus ipilimumab in patients with metastatic non-clear cell renal cell carcinoma : Real-world data from a Japanese multicenter retrospective study
© 2022 The Japanese Urological Association..
OBJECTIVES: Although nivolumab plus ipilimumab has become a standard treatment regimen for metastatic clear cell renal cell carcinoma (ccRCC), its efficacy in non-clear cell carcinoma (nccRCC) has not been fully examined. In the current study, we evaluated the clinical outcomes of nivolumab plus ipilimumab in nccRCC compared with ccRCC.
METHODS: We retrospectively analyzed 22 patients with metastatic and/or locally advanced unresectable nccRCC who received nivolumab plus ipilimumab as a first-line therapy and compared them with 107 patients with ccRCC. Objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and toxicity were compared between the nccRCC and ccRCC groups.
RESULTS: The histology of nccRCC included eight papillary, six unclassified, three chromophobe, two collecting duct carcinoma, and three other subtypes. Best objective response in nccRCC patients included three complete responses and five partial responses, resulting in an ORR of 36%, while that in ccRCC patients was 50% (p = 0.22). With a median follow-up of 11.9 months, OS was significantly shorter in patients with nccRCC than in those with ccRCC (median 20.8 months vs. not reached, p = 0.04), while there was no significant difference in PFS (median 6.3 vs. 10.8 months, p = 0.21). Treatment-related adverse events occurred in 14 (64%) nccRCC patients and 81 (76%) ccRCC patients.
CONCLUSIONS: Combination treatment with nivolumab and ipilimumab demonstrated modest clinical efficacy in patients with nccRCC compared with patients with ccRCC, suggesting it could be a therapeutic option for metastatic nccRCC patients.
| Errataetall: |
CommentIn: Int J Urol. 2023 Sep;30(9):721-722. - PMID 36653155 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:30 |
|---|---|
| Enthalten in: |
International journal of urology : official journal of the Japanese Urological Association - 30(2023), 9 vom: 21. Sept., Seite 714-721 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Izumi, Keita [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
31YO63LBSN |
|---|
| Anmerkungen: |
Date Completed 28.09.2023 Date Revised 28.09.2023 published: Print-Electronic CommentIn: Int J Urol. 2023 Sep;30(9):721-722. - PMID 36653155 Citation Status MEDLINE |
|---|
| doi: |
10.1111/iju.15128 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM350527717 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM350527717 | ||
| 003 | DE-627 | ||
| 005 | 20231226045213.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/iju.15128 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1168.xml |
| 035 | |a (DE-627)NLM350527717 | ||
| 035 | |a (NLM)36541136 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Izumi, Keita |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical outcomes of nivolumab plus ipilimumab in patients with metastatic non-clear cell renal cell carcinoma |b Real-world data from a Japanese multicenter retrospective study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.09.2023 | ||
| 500 | |a Date Revised 28.09.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Int J Urol. 2023 Sep;30(9):721-722. - PMID 36653155 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 The Japanese Urological Association. | ||
| 520 | |a OBJECTIVES: Although nivolumab plus ipilimumab has become a standard treatment regimen for metastatic clear cell renal cell carcinoma (ccRCC), its efficacy in non-clear cell carcinoma (nccRCC) has not been fully examined. In the current study, we evaluated the clinical outcomes of nivolumab plus ipilimumab in nccRCC compared with ccRCC | ||
| 520 | |a METHODS: We retrospectively analyzed 22 patients with metastatic and/or locally advanced unresectable nccRCC who received nivolumab plus ipilimumab as a first-line therapy and compared them with 107 patients with ccRCC. Objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and toxicity were compared between the nccRCC and ccRCC groups | ||
| 520 | |a RESULTS: The histology of nccRCC included eight papillary, six unclassified, three chromophobe, two collecting duct carcinoma, and three other subtypes. Best objective response in nccRCC patients included three complete responses and five partial responses, resulting in an ORR of 36%, while that in ccRCC patients was 50% (p = 0.22). With a median follow-up of 11.9 months, OS was significantly shorter in patients with nccRCC than in those with ccRCC (median 20.8 months vs. not reached, p = 0.04), while there was no significant difference in PFS (median 6.3 vs. 10.8 months, p = 0.21). Treatment-related adverse events occurred in 14 (64%) nccRCC patients and 81 (76%) ccRCC patients | ||
| 520 | |a CONCLUSIONS: Combination treatment with nivolumab and ipilimumab demonstrated modest clinical efficacy in patients with nccRCC compared with patients with ccRCC, suggesting it could be a therapeutic option for metastatic nccRCC patients | ||
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a immune checkpoint inhibitor | |
| 650 | 4 | |a ipilimumab | |
| 650 | 4 | |a metastatic renal cell carcinoma | |
| 650 | 4 | |a nivolumab | |
| 650 | 4 | |a non-clear cell renal cell carcinoma | |
| 650 | 7 | |a Ipilimumab |2 NLM | |
| 650 | 7 | |a Nivolumab |2 NLM | |
| 650 | 7 | |a 31YO63LBSN |2 NLM | |
| 700 | 1 | |a Inoue, Masaharu |e verfasserin |4 aut | |
| 700 | 1 | |a Washino, Satoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Shirotake, Suguru |e verfasserin |4 aut | |
| 700 | 1 | |a Kagawa, Makoto |e verfasserin |4 aut | |
| 700 | 1 | |a Takeshita, Hideki |e verfasserin |4 aut | |
| 700 | 1 | |a Miura, Yuji |e verfasserin |4 aut | |
| 700 | 1 | |a Hyodo, Yoji |e verfasserin |4 aut | |
| 700 | 1 | |a Oyama, Masafumi |e verfasserin |4 aut | |
| 700 | 1 | |a Kawakami, Satoru |e verfasserin |4 aut | |
| 700 | 1 | |a Miyagawa, Tomoaki |e verfasserin |4 aut | |
| 700 | 1 | |a Saito, Kazutaka |e verfasserin |4 aut | |
| 700 | 1 | |a Kageyama, Yukio |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of urology : official journal of the Japanese Urological Association |d 1996 |g 30(2023), 9 vom: 21. Sept., Seite 714-721 |w (DE-627)NLM075183226 |x 1442-2042 |7 nnns |
| 773 | 1 | 8 | |g volume:30 |g year:2023 |g number:9 |g day:21 |g month:09 |g pages:714-721 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/iju.15128 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 30 |j 2023 |e 9 |b 21 |c 09 |h 714-721 | ||